STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial

SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented today as a digital oral presentation (DOP83) at the 16th Congress of the European Crohn’s and Colitis Organisation.1 “Despite recent substantial therapeutic gains, many patients living with ulcerative colitis still struggle to find lasting relief from their disease symptoms, especially without the use of steroids that can be associated with debilitating side effects when used long-term,” said Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) at the Icahn Institute for Medicine at Mount Sinai.b “The LTE of the UNIFI study underscores the importance of studying therapies long-term, with results showing ustekinumab as both an effective and enduring treatment option for patients living with moderat...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

Prevalences, nuances of presentation, and likely clinical course of myocarditis after use of some vaccines against SARS-CoV-2 are in sharper view after additions to the literature this week.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Immune checkpoint inhibitors can be effective in patients with non-small cell lung cancer and mild interstitial lung disease, but with a greater risk.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Pulmonary Medicine News Source Type: news
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
In the article “New treatments for chronic urticaria” by P Kolkhir et al (Ann Allergy Asthma Immunl 2020:124(1): 2-12), the following text has been removed. The article has been corrected online at https://doi.org/10.1016/j.anai.2019.08.014.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
Technology is one of those items with which all clinicians (probably everyone) seem to have a love-hate relationship. The electronic medical record has made documenting and billing patient encounters much easier, yet at the same time, it seems to have erected a barrier between the patient and provider. Along with the growth of the electronic health record has been an explosion in the use of handheld devices and health-related applications (apps). These apps allow for more engagement and involvement with patients, including health monitoring by providers.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
We thank the respondents to our article1 for their insightful comments. Although we have matched subjects in both cohorts by age, sex, comorbidities, and index date, Lin et  al2 indicate a lack of adjustment for co-medication status, including the use of corticosteroids and disease-modifying antirheumatic drugs (DMARDs), in the propensity score. We agree that these medications are important confounders on fracture. We therefore had conducted multivariate analysis in t he published article by adjustment for corticosteroids, DMARDs, and phototherapy.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Commentary Source Type: research
We read with great interest the article by Lin et  al1 reporting the association of incidental fractures in patients with atopic dermatitis (AD). We appreciate the authors who collected data from Taiwan's National Health Insurance Research Database and conducted a great cohort study. Nevertheless, we highlight some key points.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy | Allergy & Immunology | Arthritis | Babies | Babies Heart Conditions | Back Pain | Bleeding | Brain | Brain Cancers | Breast Needle Aspiration | Breastfed | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Child Development | Children | Chronic Pain | Colon Cancer | Colorectal Cancer | Complementary Medicine | Corticosteroid Therapy | Cough | Crohn's Disease | ENT & OMF | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Headache | Health Management | Heart | Herbs | Hospitals | Hypertension | Infectious Diseases | Inflammatory Bowel Disease | Learning | Legislation | Marketing | Methotrexate | Migraine | Milk | Neurology | Neuroscience | Nurses | Nursing | Oral Cancer | Pain | Pharmaceuticals | Politics | Pregnancy | Profits and Losses | Psoriasis | Psoriatic Arthritis | Pulmonary Hypertension | Respiratory Medicine | Rheumatology | Science | Skin | Skin Cancer | Sore Throat | Stelara | Study | Training | Tuberculosis | Tuberculosis (BCG) Vaccine | Ulcerative Colitis | Universities & Medical Training | Urinary Tract Infections | USA Health | Vaccines | Vitamins | Weight Loss